This is the authors' abstract. We don't add key points for this paper.
Antimicrobial activity of three kinds of commercially available montmorillonite nano-clays including a naturally occurring one (Cloisite Na+) and two organically modified ones (Cloisite 20A and Cloisite 30B) against four representative pathogenic bacteria (two Gram-positive ones such as Staphylococcus aureus and Listeria monocytogenes, and two Gram-negative ones such as Salmonella typhimurium and E. coli O157:H7) was investigated. Antimicrobial activity was found to be dependent on the type of nano-clay and microorganisms tested. Among the nano-clays tested, Cloisite 30B showed the highest antibacterial activity followed by Cloisite 20A, however, the unmodified montmorillonite (Cloisite Na+) did not show any antibacterial activity. Especially, Cloisite 30B inactivated Gram-positive bacteria completely within an hour of incubation and inactivated Gram-negative bacteria by more than 2-3 log cycles after 8 hours incubation. SEM and TEM images of cell structure indicated that the organically modified nano-clay caused rupture of cell membrane and inactivation of the bacteria. This finding of antimicrobial activity of the organo-clay would open a new opportunity to develop polymer nanocomposites with additional functionality, i.e., antimicrobial function.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: